Regulatory T cell therapy in autoimmune and immune-mediated diseases: from basic research to clinical practice and future perspectives.

MS In randomized, double-blind, placebo-controlled trials involving patients with MS, IL-2 therapy elicited modest and delayed Treg expansion, with some patients demonstrating elevated Treg frequencies and enhanced activation phenotypes; however, the response was relatively attenuated compared to that observed in other autoimmune diseases, and clinical benefits did not reach statistical significance ( 67 ).

also in 111,027 other papers